R&G PharmaStudies Co., Ltd. (SHE:301333)
China
· Delayed Price · Currency is CNY 63.47
-2.36 (-3.58%)
At close: Apr 29, 2026
R&G PharmaStudies Market Cap
R&G PharmaStudies has a market cap or net worth of 6.09 billion as of April 29, 2026. Its market cap has increased by 20.83% in one year.
Market Cap
6.09B
Enterprise Value
4.42B
Revenue
896.26M
Ranking
n/a
PE Ratio
45.29
Stock Price
63.47
Market Cap Chart
Since August 2, 2022, R&G PharmaStudies's market cap has increased from 5.40B to 6.09B, an increase of 12.81%. That is a compound annual growth rate of 3.27%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 29, 2026 | 6.09B | 7.54% |
| Dec 31, 2025 | 5.67B | 19.12% |
| Dec 31, 2024 | 4.76B | -23.17% |
| Dec 29, 2023 | 6.19B | 25.30% |
| Dec 30, 2022 | 4.94B | -8.52% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Xiangxue Pharmaceutical | 6.28B |
| Innovita Biological Technology | 6.20B |
| Shouyao Holdings (Beijing) Co., LTD. | 5.98B |
| Lifecome Biochemistry | 5.96B |
| Wuhan Keqian Biology Co.,Ltd | 6.74B |
| PharmaResources (Shanghai) | 5.90B |
| Novogene | 5.90B |
| Shenzhen Weiguang Biological Products | 5.88B |